Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2022 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth trajectories that the company already serves, with early and large ramp ahead. Key elements: management speaks about specific customers/tenants and their plans, the company is already inside that growth (leases signed, construction underway), and the trajectory is early/large. In the transcript, Doug Linde discusses specific tenants: Wellington (lease at 140 Kendrick), AstraZeneca (lease at 290 Binney), Perella Weinberg (renewal at GM), etc. He describes their decisions and how BXP accommodated them. However, the question asks if the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers... such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Management does mention specific tenants and their actions, but the focus is on BXP's leasing activity and portfolio performance. The forward guidance is based on BXP's own leasing, development pipeline, and market conditions. The counterparties' trajectories are not the primary driver; rather, BXP's own execution and market quality are emphasized. The tenants' plans are mentioned as individual transactions, not as a coherent narrative of counterparties scaling up that BXP supplies. Also, the company is diversified across many tenants, not dependent on a few. The growth is from BXP's own leasing efforts and development. The question asks if a substantial part of management's forward account consists of reporting on counterparties' own growth. Here, management discusses its own leasing volume, occupancy, and development pipeline. The tenants are examples of deals, not a narrative of their expansion driving BXP. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.